WO2022228538A1 - 一种表达免疫调节因子的car载体及其应用 - Google Patents
一种表达免疫调节因子的car载体及其应用 Download PDFInfo
- Publication number
- WO2022228538A1 WO2022228538A1 PCT/CN2022/090106 CN2022090106W WO2022228538A1 WO 2022228538 A1 WO2022228538 A1 WO 2022228538A1 CN 2022090106 W CN2022090106 W CN 2022090106W WO 2022228538 A1 WO2022228538 A1 WO 2022228538A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- car
- cells
- tumor
- nucleic acid
- application
- Prior art date
Links
- 239000013598 vector Substances 0.000 title description 6
- 230000001105 regulatory effect Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 92
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims abstract description 37
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims abstract description 35
- 230000002147 killing effect Effects 0.000 claims abstract description 28
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 16
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 16
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 16
- 239000013604 expression vector Substances 0.000 claims abstract description 14
- 230000008595 infiltration Effects 0.000 claims abstract description 14
- 238000001764 infiltration Methods 0.000 claims abstract description 14
- 230000000694 effects Effects 0.000 claims abstract description 13
- 239000012634 fragment Substances 0.000 claims abstract description 5
- 210000004027 cell Anatomy 0.000 claims description 123
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 37
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 33
- 210000004881 tumor cell Anatomy 0.000 claims description 32
- 210000004443 dendritic cell Anatomy 0.000 claims description 11
- 239000000427 antigen Substances 0.000 claims description 10
- 102000036639 antigens Human genes 0.000 claims description 10
- 108091007433 antigens Proteins 0.000 claims description 10
- 102100037850 Interferon gamma Human genes 0.000 claims description 8
- 108010074328 Interferon-gamma Proteins 0.000 claims description 8
- 108010002350 Interleukin-2 Proteins 0.000 claims description 8
- 102000000588 Interleukin-2 Human genes 0.000 claims description 8
- 101150029707 ERBB2 gene Proteins 0.000 claims description 6
- 230000002519 immonomodulatory effect Effects 0.000 claims description 6
- 241000713666 Lentivirus Species 0.000 claims description 5
- 208000007433 Lymphatic Metastasis Diseases 0.000 claims description 5
- 230000000139 costimulatory effect Effects 0.000 claims description 5
- 230000028993 immune response Effects 0.000 claims description 4
- 230000028327 secretion Effects 0.000 claims description 4
- 102100025221 CD70 antigen Human genes 0.000 claims description 3
- -1 Claudin18.2 Proteins 0.000 claims description 3
- 102100027627 Follicle-stimulating hormone receptor Human genes 0.000 claims description 3
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims description 3
- 101000862396 Homo sapiens Follicle-stimulating hormone receptor Proteins 0.000 claims description 3
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 3
- 102100023123 Mucin-16 Human genes 0.000 claims description 3
- 238000004873 anchoring Methods 0.000 claims description 3
- 230000004068 intracellular signaling Effects 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000008685 targeting Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 230000014207 opsonization Effects 0.000 claims 1
- 230000003832 immune regulation Effects 0.000 abstract description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 abstract 2
- 230000008106 antitumoral immune reaction Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 51
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 210000001165 lymph node Anatomy 0.000 description 16
- 201000001441 melanoma Diseases 0.000 description 14
- 206010033128 Ovarian cancer Diseases 0.000 description 13
- 206010061535 Ovarian neoplasm Diseases 0.000 description 13
- 239000002609 medium Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 238000001514 detection method Methods 0.000 description 9
- 210000002865 immune cell Anatomy 0.000 description 9
- 238000007920 subcutaneous administration Methods 0.000 description 9
- 230000012010 growth Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 238000011740 C57BL/6 mouse Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102100022297 Integrin alpha-X Human genes 0.000 description 4
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 4
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 208000007660 Residual Neoplasm Diseases 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 3
- 238000003125 immunofluorescent labeling Methods 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 2
- 208000006678 Abdominal Neoplasms Diseases 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 238000001815 biotherapy Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 231100000225 lethality Toxicity 0.000 description 2
- 230000006996 mental state Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 238000011357 CAR T-cell therapy Methods 0.000 description 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000026058 directional locomotion Effects 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003236 esophagogastric junction Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000007959 normoxia Effects 0.000 description 1
- 208000011932 ovarian sarcoma Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 108010056030 retronectin Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/001139—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464436—Cytokines
- A61K39/464439—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/867—Retroviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Definitions
- the invention belongs to the field of bioengineering, and in particular relates to a CAR expression vector and its application.
- Chimeric antigen receptor-modified T cells have shown good clinical effects in the treatment of hematological tumors such as acute B-cell lymphoma, but they are not effective in solid tumors.
- the CAR structure consists of three parts, namely the extracellular region for recognizing tumor antigens, the transmembrane region for anchoring the CAR structure, and the intracellular T cell activation signaling domain.
- the killing of tumor cells by CAR-T relies on the specific binding of the extracellular single-chain variable region to the corresponding tumor-associated antigen, and then initiates downstream signaling through the intracellular signaling domain, causing the activation and proliferation of CAR-T cells, and by releasing IFN - Cytokines such as gamma exert cytotoxicity.
- IFN - Cytokines such as gamma exert cytotoxicity.
- the current traditional CAR-T is not effective.
- the intracellular region of the first-generation CAR structure has only 3 ITAM sequences of CD3 ⁇ or 2 ITAM sequences of FcR ⁇ , which can only provide the first signal of T cell activation, limited ability to secrete IL-2, and weak proliferation ability. Satisfactory results were not obtained.
- the second-generation CAR structure adds a tandem costimulatory molecule signal domain after the intracellular signal sequence, and the proliferation and killing capacity are improved compared with the first-generation.
- the intracellular signal of the third-generation CAR structure contains more costimulatory domains, however, studies have shown that its killing activity is not significantly improved, and the side effects are greater.
- the fourth-generation CAR is based on the second-generation CAR to introduce new functional elements to enhance the anti-tumor activity of CAR-T cells, such as CAR-T that secretes cytokines IL-12, IL-15 or IL-18, which can enhance CAR-T cells.
- CAR-T that secretes cytokines IL-12, IL-15 or IL-18, which can enhance CAR-T cells.
- cytokines IL-12, IL-15 or IL-18 which can enhance CAR-T cells.
- CAR-T cancer-associated fibroblasts
- the tumor microenvironment can also help tumor cells evade immune surveillance, inhibit the body's anti-tumor response, and inhibit the infiltration, proliferation and survival of CAR-T cells, which is also the main reason for the ineffectiveness of CAR-T cells against solid tumors. one. Therefore, designing and constructing a CAR-T cell that can effectively infiltrate the tumor tissue and reverse the tumor immunosuppressive microenvironment can overcome the low response rate of the existing immunotherapy and have a more effective anti-tumor effect.
- the present invention constructs a new type of CAR-T cell (CAR-GM-T) with high expression of GM-CSF on the basis of the improved second-generation CAR, which can alleviate the defects and deficiencies in the existing technology. .
- the purpose of the present invention is to provide a novel CAR expression vector and its application.
- the technical scheme of the present invention is:
- a CAR expression vector comprising a nucleic acid encoding a chimeric antigen receptor (CAR) and a nucleic acid encoding an immunomodulatory factor, wherein the nucleic acid encoding the immunomodulatory factor is a granulocyte-macrophage colony stimulating factor encoding (GM-CSF) nucleic acid full length or fragment.
- CAR chimeric antigen receptor
- GM-CSF granulocyte-macrophage colony stimulating factor encoding
- nucleic acid encoding the chimeric antigen receptor and the nucleic acid encoding the granulocyte-macrophage colony stimulating factor are linked by a sequence encoding the self-cleaving peptide P2A.
- nucleic acid encoding the chimeric antigen receptor also includes an extracellular region targeting a specific tumor antigen, a transmembrane region anchoring the CAR structure, and an intracellular signaling domain containing multiple costimulatory molecules in series, Including CD3 ⁇ chain, 4-1BB and GM-CSF.
- the targets targeting specific tumor antigens include one or more of Her2, B7-H3, Claudin18.2, CD70, MUC16, FSHR, FR or Meso.
- Her2 mainly targets HER2-positive breast cancer, lung cancer, gastric cancer, ovarian cancer and sarcoma; Meso targets pancreatic cancer, ovarian cancer and lung cancer; B7-H3 and CD70 target melanoma, followed by MUC16, Both FSHR and FR target ovarian cancer.
- Clasdin18.2 targets gastric cancer, esophagogastric junction cancer and pancreatic cancer.
- a lentivirus comprising the above-mentioned CAR expression vector, the lentivirus includes pWPXLd, psPAX2 and/or pMD2.G.
- a CAR-T cell expressing the above-mentioned chimeric antigen receptor A CAR-T cell expressing the above-mentioned chimeric antigen receptor.
- the solid tumors mainly include breast cancer, ovarian cancer and lung cancer, but are not limited thereto.
- the CAR-T cells can enhance the secretion of GM-CSF, IFN- ⁇ and IL-2.
- the CAR-T cells directly enhance the killing activity of CAR-T cells by expressing granulocyte-macrophage colony-stimulating factor.
- the CAR-T cells can enhance the infiltration ability, and more CAR-T cells can infiltrate into the solid tumor to exert the effect of specifically killing tumor cells.
- the CAR-T cells after the CAR-T cells infiltrate into the solid tumor, they express granulocyte-macrophage colony-stimulating factor to play an immunoregulatory function to regulate the tumor microenvironment.
- the CAR-T cells activate and recruit dendritic cells into the solid tumor by expressing granulocyte-macrophage colony-stimulating factor to activate the antigen-specific tumor immune response of endogenous T cells.
- the CAR-T cells can inhibit the lymph node metastasis of tumor cells.
- the "chemotaxis" mentioned in the present invention refers to the CAR-T prepared by the present invention, namely CAR-GM-T, which promotes the directional movement of DC cells to tumor cells.
- DC cells are professional antigen-presenting cells in the body, express MHC II and costimulatory molecules, and can ingest, capture, and process tumor antigens, and then migrate to lymph nodes to activate the body's endogenous T cell anti-tumor immune response.
- the present invention constructs a CAR-T cell (CAR-GM-T) with high expression of GM-CSF on the basis of the second-generation CAR-T.
- CAR-GM-T CAR-T cell
- GM-CSF is an important immunomodulator, GM-CSF can activate T cell immune response by activating and recruiting dendritic cells (DC), and can also activate other immune cells such as granulocytes, macrophages and NK cells play an important role in the regulation of tumor immune responses.
- DC dendritic cells
- the CAR-GM-T cells constructed in the present invention can highly express GM-CSF, which can not only directly enhance the killing activity and proliferation ability of the CAR-T cells themselves, but also make the CAR-T cells stronger than ordinary CAR-T cells. Cells have stronger immune regulation functions.
- the CAR-GM-T cells prepared by the present invention have outstanding effects in the following aspects:
- CAR-GM-T can significantly inhibit the growth of melanoma, and significantly prolong the survival time of experimental animals
- CAR-GM-T has a stronger ability to infiltrate solid tumor tissue than conventional CAR-T cells, and exerts a stronger anti-tumor effect after infiltrating into solid tumors;
- the present invention can reshape and reverse the tumor microenvironment, directly or assist in enhancing the activity of T cells, and provide a new strategy for the treatment of solid tumors.
- Fig. 1 is the construction diagram of CAR-hGM expression vector
- Figure 2 shows that GM-CSF secreted by CAR-GM-T cells is significantly higher than that of conventional CAR-T cells
- Figure 3 is a graph of the killing activity of CAR-GM-T cells
- Figure 4 shows that the killing efficiency of Meso-CAR-GM-T cells on SK-OV3-Meso is significantly higher than that of Meso-CAR-T, and the killing efficiency increases with the increase of the effector-target ratio;
- Figure 5 shows the GM-CSF secreted when CAR-GM-T kills tumor cells, which is significantly higher than that of conventional CAR-T cells;
- Figure 6 shows that when the effector-target ratio is 5:1, the IFN- ⁇ secreted by CAR-GM-T cells is 4.5 times that of conventional CAR-T cells, and when CAR-GM-T cells contact tumor cells at different effector-target ratios The IFN- ⁇ was significantly higher than that of conventional CAR-T cells;
- Figure 7 shows that IL-2 secreted by CAR-GM-T cells in killing tumor cells is also significantly enhanced under different effector-target ratios
- Figure 8 is a graph showing the effect of CAR-GM-T cells in the treatment of abdominal tumors in mice
- Figure 9 shows that conventional CAR-T has no obvious inhibitory effect on the growth of B16F10-Her2 subcutaneous melanoma xenografts, nor can it prolong the survival of mice, while CAR-GM-T treatment can significantly inhibit the growth of melanoma xenografts in mice;
- FIG. 10 shows that CAR-GM-T treatment can significantly prolong the survival time of mice
- Figure 11 is a graph showing the proportion of CAR-T cells in the tumor and lymph node of the mouse on the 24th day after the mice were treated, isolated and prepared as a single cell suspension;
- Figure 12 shows the further detection of CAR-GM-T infiltration in human tumor tissue. 28 days after the treatment of abdominal tumor in NSG mice, the residual tumor in the abdominal cavity was taken for immunofluorescence staining to detect the infiltration of CD3 + T cells;
- Figure 13 shows that the CD45.2 + immune cells in the conventional CAR-T treatment group accounted for only 5%, and the infiltration of immune cells in the tumor of the mice in the CAR-GM-T treatment group was significantly better than that in the conventional CAR-T treatment group;
- Figure 14 shows that CD3 + T lymphocytes in the tumors of mice in the CAR-GM-T treatment group accounted for 11% of the CD45.2 + cells, while the CD3 + T lymphocytes in the conventional CAR-T treatment group accounted for only 5%, indicating that high Expression of GM-CSF significantly increased the proportion of endogenous CD3 + T cells in mouse tumors after CAR-T cell therapy;
- Figure 15 shows that the proportion of CD11c + MHCII hi DC cells in the tumor in the CAR-GM-T treatment group was significantly higher than that in the conventional CAR-T treatment group;
- Figure 16 shows the results of HE staining of the draining lymph nodes, showing that CAR-GM-T can inhibit the lymph node metastasis of tumor cells.
- the term "about” is typically expressed as +/- 5% of the stated value, more typically +/- 4% of the stated value, and more typically + /-3%, more typically +/-2% of said value, even more typically +/-1% of said value, even more typically +/-0.5% of said value.
- Human ovarian cancer cell line (SK-OV3-Luc) expressing luciferase and mouse melanoma cell line (B16F10-Her2) overexpressing Her2 protein were preserved by the State Key Laboratory of Biotherapy, Sichuan University. 10% calf serum in DMEM medium, 37°C, 5% CO 2 , and cultured under normoxia.
- Her2-CAR and hGM-CSF were linked with the self-cleaving polypeptide P2A to construct a Her2-CAR-hGM expression vector (pWPXLd-Her2-CAR-hGM-CSF) with high expression of hGM-CSF ( Figure 1).
- the Her2-CAR-P2A fragment was amplified with the pWPXLd-Her2-CAR-EGFP vector as the template, and the hGM-CSF fragment was amplified with the pWPXLd-hGM-CSF vector as the template.
- the vector pWPXLd was linearized with restriction enzymes BamHI and EcoRI, and the fragments Her2-CAR and hGM-CSF were ligated into the linearized vector pWPXLd by homologous recombination.
- Lentiviral packaging was performed using a lentiviral three-plasmid system.
- the plasmid transduction method was calcium phosphate-DNA co-precipitation method
- the helper plasmids were psPAX2 and pMD2.G
- the packaging cells were 293T cells.
- 48 hours and 72 hours after transfection the virus supernatant was collected respectively, and the virus supernatant was filtered with a 0.22 ⁇ m disposable syringe filter (PES membrane). °C refrigerator.
- peripheral blood mononuclear lymphocytes According to the number of peripheral blood mononuclear lymphocytes, take out an appropriate amount of Human T-Expander CD3/CD28 Dynabeads magnetic beads, wash the magnetic beads once with 5 mL of DPBS, and resuspend in T cell complete medium. The peripheral blood mononuclear lymphocyte suspension was mixed with the washed magnetic beads and placed in a T75 culture at 37 °C, 5% CO 2 .
- peripheral blood mononuclear lymphocytes According to the number of peripheral blood mononuclear lymphocytes, take out an appropriate amount of Human T-Expander CD3/CD28 Dynabeads magnetic beads, wash the magnetic beads once with 5 mL of DPBS, and resuspend in T cell complete medium. The peripheral blood mononuclear lymphocyte suspension was mixed with the washed magnetic beads and placed in a T75 culture at 37 °C, 5% CO 2 .
- the secretion of cytokines was determined by ELISA, including IL-2, IFN ⁇ , and GM-CSF.
- the samples were derived from the culture supernatant of CAR-T cells or the supernatant after CAR-T cells killed tumor cells.
- LDH lactate dehydrogenase
- each effector-target ratio is set to the following 6 groups MOCK T (effect Spontaneous cell group), MOCK T+Tumor (experimental group), CAR-T, CAR-T+Tumor, CAR-GM-CSF-T, CAR-GM-CSF-T+Tumor, 3 sub-wells in each group, simultaneously The blank medium group, the spontaneous tumor cell group, and the tumor cell maximal release group were set, and the final volume of each well was 200 ⁇ L.
- MOCK T effect Spontaneous cell group
- MOCK T+Tumor experimental group
- the blank medium group, the spontaneous tumor cell group, and the tumor cell maximal release group were set, and the final volume of each well was 200 ⁇ L.
- mice Regularly monitor the body weight of mice.
- mice On the 6th day after inoculation, each mouse was imaged in vivo, and the mice were divided into 3 groups according to the fluorescence value of the image, with 6 mice in each group, namely the PBS group, the Her2-CAR group, and the Her2-CAR group. -GM-CSF group.
- mice Regularly monitor the mice's mental state, activity, hair gloss, and eating conditions, observe whether there are adverse reactions, and detect the weight of the mice.
- mice were anesthetized and sacrificed by de-neck, and the residual tumor in the abdominal cavity was taken for immunofluorescence staining to detect the infiltration of CAR-T cells.
- mice can be used for the construction of subcutaneous xenograft models after acclimating to the environment for 1 week.
- each tumor-bearing mouse was injected with cyclophosphamide at a dose of 200 mg/kg, intraperitoneally.
- mice On the 12th day after inoculation, the volume of the transplanted tumor was measured, and the mice were divided into 3 groups according to the tumor volume, with 15 mice in each group, namely the PBS group, the Her2-CAR group, and the Her2-CAR-GM-CSF group.
- Her2-CAR-T and Her2-CAR-GM-CSF-T cells prepared from lymphocytes of C57BL/6 CD45.1 mice with good growth status, and resuspend them in 1640 medium to The final concentration is 3*10 ⁇ 7/mL.
- mice were sacrificed by decapitation after anesthesia, and the spleen, draining lymph nodes, lymph nodes, and tumors of the mice were isolated, and HE staining and flow cytometry were performed respectively.
- the killing efficiency of Her2-CAR-GM-T cells to SK-OV3 cells naturally expressing Her2 protein was significantly higher than that of Her2-CAR-T, and the killing efficiency was enhanced with the increase of the effective-target ratio.
- the killing efficiency of Her2-CAR-GM-T cells to SK-OV3 reached 30% when the effector-target ratio was 1:1, which was significantly higher than that of the Her2-CAR-T group (P ⁇ 0.001), while Her2-CAR-T
- Meso CAR-T is a meso-targeted CAR-T therapy developed by the University of Pennsylvania and Novartis, and Meso CAR-T is also Novartis' first CAR-T product for solid tumors, with indications including ovarian cancer, lung cancer and Pancreatic cancer.
- CAR-T had no obvious inhibitory effect on the growth of B16F10-Her2 subcutaneous melanoma xenografts, and could not prolong the survival of mice, while CAR-GM-T treatment could significantly inhibit the growth of melanoma xenografts in mice (P ⁇ 0.05).
- Fig. 9 the survival time of mice was significantly prolonged (Fig. 10).
- the tumors and lymph nodes of the mice were isolated and prepared as single-cell suspensions, and the proportion of CAR-T cells in the tumors and lymph nodes of the mice was detected by flow cytometry.
- the results showed that the CAR + T cells in the conventional CAR-T treatment group accounted for 1.2% of the CD3 + T cells, while the intratumor CAR + T cells in the CAR-GM-T treatment group accounted for 2.4% of the CD3 + T cells . -2 times of T treatment group, the difference was statistically significant (P ⁇ 0.01).
- CAR + T cells in the tumor-draining lymph nodes of the conventional CAR-T treatment group accounted for only 0.04% of CD3 + T cells, while the CAR-GM-T treatment group of mice
- the CAR + T cells in the tumor-draining lymph nodes accounted for 0.4% of the CD3 + T cells, which was 10 times that of the conventional CAR-T treatment group and significantly higher than the conventional CAR-T treatment group (P ⁇ 0.01) ( Figure 11).
- Endogenous immune cells of CD45.2 + were analyzed in mouse tumor cells, and the infiltration of endogenous immune cells was analyzed.
- the results showed that CD45.2 + immune cells accounted for 8% in the tumors of the mice in the CAR-GM-T treatment group, while the CD45.2 + immune cells in the CAR-T treatment group accounted for only 5%.
- the infiltration of immune cells in the tumor of the mice was significantly better than that of the CAR-T treatment group (P ⁇ 0.05) ( Figure 13).
- CD3 + T lymphocytes were analyzed among CD45.2 + endogenous immune cells. The results showed that CD3 + T lymphocytes in the tumors of the mice in the CAR-GM-T treatment group accounted for 11% of the CD45.2 + cells, while the CD3 + T lymphocytes in the CAR-T treatment group accounted for only 5%, indicating a high expression of CD3+ T lymphocytes.
- GM-CSF significantly increased the proportion of endogenous CD3 + T cells in mouse tumors after CAR-T cell treatment (P ⁇ 0.01) (Fig. 14).
- CD11b + CD11c + cells were analyzed among CD45.2 + cells, and CD11c + MHCII hi DC cells were analyzed from this fraction of cells.
- the results showed that the proportion of CD11c + MHCII hi DC cells in the tumor in the CAR-GM-T treatment group was significantly higher than that in the conventional CAR-T treatment group (P ⁇ 0.01) ( Figure 15), indicating that the tumor in the CAR-GM-T treatment group more mature DC cells.
- CAR-GM-T cells inhibit tumor cell lymph node metastasis
- B16F10 is a high-metastatic mouse melanoma cell line.
- the team of the present invention used CAR-T cells and CAR-GM-T cells to treat the B16F10-Her2 melanoma subcutaneous transplanted tumor model.
- the results of HE staining of the draining lymph nodes showed that there were a large number of melanin plaques in the PBS treatment group, a small amount of melanin plaques in the CAR-T treatment group, and a large number of lymphocytes and no melanin plaques in the CAR-GM-T treatment group.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (13)
- 一种CAR表达载体,其包括编码嵌合抗原受体的核酸及编码免疫调节因子的核酸,其特征在于,所述编码免疫调节因子的核酸为编码粒细胞-巨噬细胞集落刺激因子的核酸全长或片段。
- 如权利要求1所述的CAR表达载体,其特征在于,所述编码嵌合抗原受体的核酸与所述编码粒细胞-巨噬细胞集落刺激因子的核酸通过编码自切割肽P2A的序列连接。
- 如权利要求1所述的CAR表达载体,其特征在于,所述编码嵌合抗原受体的核酸还包括靶向特异性肿瘤抗原的胞外区、锚定CAR结构的跨膜区和含有串联的共刺激分子的胞内信号传导结构域,所述胞内信号传导结构域包括CD3ζ链、4-1BB和GM-CSF。
- 如权利要求3所述的CAR表达载体,其特征在于,所述靶向特异性肿瘤抗原的靶点包括Her2、B7-H3、Claudin18.2、CD70、MUC16、FSHR、FR或Meso中的一种或多种。
- 包含权利要求1-4任一项所述CAR表达载体的慢病毒,其特征在于,所述慢病毒包括pWPXLd、psPAX2和/或pMD2.G。
- 一种CAR-T细胞,其特征在于,表达权利要求1-4任一项所述的嵌合抗原受体。
- 权利要求6所述的CAR-T细胞在制备抗实体肿瘤药物中的应用。
- 如权利要求7所述的应用,其特征在于,所述CAR-T细胞可以增强GM-CSF、IFN-γ和IL-2分泌。
- 如权利要求7所述的应用,其特征在于,所述CAR-T细胞通过表达粒细胞-巨噬细胞集落刺激因子直接增强CAR-T细胞杀伤活性。
- 如权利要求7所述的应用,其特征在于,所述CAR-T细胞可以增强浸润能力,更多的CAR-T细胞可以浸润到实体瘤内部发挥特异性杀伤肿瘤细胞的效力。
- 如权利要求10所述的应用,其特征在于,所述CAR-T细胞浸润到实体瘤内部后可以发挥免疫调理功能调控肿瘤微环境。
- 如权利要求11所述的应用,其特征在于,所述CAR-T细胞可以激活和招募树突状细胞到所述实体瘤内部,以激活内源性T细胞的抗原特异性肿瘤免疫反应。
- 如权利要求7所述的应用,其特征在于,所述CAR-T细胞能抑制肿瘤细胞的淋巴结转移。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2022263746A AU2022263746A1 (en) | 2021-04-30 | 2022-04-29 | Car vector expressing immune regulatory factor and application thereof |
GB2318060.7A GB2621770A (en) | 2021-04-30 | 2022-04-29 | Car vector expressing immune regulatory factor and application thereof |
JP2023566450A JP2024515319A (ja) | 2021-04-30 | 2022-04-29 | 免疫調節因子を発現するcarベクター及びその応用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110481979 | 2021-04-30 | ||
CN202110481979.9 | 2021-04-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022228538A1 true WO2022228538A1 (zh) | 2022-11-03 |
Family
ID=82862040
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/090106 WO2022228538A1 (zh) | 2021-04-30 | 2022-04-29 | 一种表达免疫调节因子的car载体及其应用 |
Country Status (5)
Country | Link |
---|---|
JP (1) | JP2024515319A (zh) |
CN (1) | CN114934071B (zh) |
AU (1) | AU2022263746A1 (zh) |
GB (1) | GB2621770A (zh) |
WO (1) | WO2022228538A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117986387A (zh) * | 2023-05-31 | 2024-05-07 | 四川大学华西医院 | 一种新型小型化car设计及制备方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180028631A1 (en) * | 2016-07-29 | 2018-02-01 | Lan Bo Chen | Anti-ssea4 chimeric antigen receptors and their use for treating cancer |
CN108025024A (zh) * | 2015-07-28 | 2018-05-11 | 宾夕法尼亚大学董事会 | 表达嵌合抗原受体的修饰单核细胞/巨噬细胞及其用途 |
CN110760001A (zh) * | 2019-07-29 | 2020-02-07 | 浙江启新生物技术有限公司 | Gm-csf敲低及其中和单链抗体分泌的嵌合抗原受体t细胞构建与应用 |
CN112210018A (zh) * | 2020-10-12 | 2021-01-12 | 广东昭泰体内生物医药科技有限公司 | 一种靶向gpc3的嵌合抗原受体及其应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2013235726B2 (en) * | 2012-03-23 | 2017-04-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin chimeric antigen receptors |
EP3151854B1 (en) * | 2014-06-06 | 2020-02-26 | Memorial Sloan Kettering Cancer Center | Mesothelin-targeted chimeric antigen receptors and uses thereof |
CN105505869A (zh) * | 2015-12-21 | 2016-04-20 | 河南大学淮河医院 | 一种针对肿瘤干细胞的嵌合抗原受体t细胞 |
CN106543288A (zh) * | 2016-10-24 | 2017-03-29 | 山东兴瑞生物科技有限公司 | 一种间皮素嵌合抗原受体修饰的t细胞制备及胰腺癌治疗上的应用 |
US20200407455A1 (en) * | 2018-03-16 | 2020-12-31 | Shinshu University | Genetically modified cells and method for producing same |
CN110396131B (zh) * | 2019-08-23 | 2020-07-10 | 北京鼎成肽源生物技术有限公司 | 一种ErbB2单链抗体、靶向人ErbB2的嵌合抗原受体、重组载体、重组细胞和应用 |
CN110964121B (zh) * | 2019-12-20 | 2022-09-16 | 山东省齐鲁细胞治疗工程技术有限公司 | 一种分泌il-7、il-15因子的cd19-car-t细胞及其应用 |
CN111944760A (zh) * | 2020-08-14 | 2020-11-17 | 广东先康达生物科技有限公司 | 一种分泌双特异性抗体的免疫细胞及其应用 |
-
2022
- 2022-04-28 CN CN202210470233.2A patent/CN114934071B/zh active Active
- 2022-04-29 JP JP2023566450A patent/JP2024515319A/ja active Pending
- 2022-04-29 WO PCT/CN2022/090106 patent/WO2022228538A1/zh active Application Filing
- 2022-04-29 GB GB2318060.7A patent/GB2621770A/en active Pending
- 2022-04-29 AU AU2022263746A patent/AU2022263746A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108025024A (zh) * | 2015-07-28 | 2018-05-11 | 宾夕法尼亚大学董事会 | 表达嵌合抗原受体的修饰单核细胞/巨噬细胞及其用途 |
US20180028631A1 (en) * | 2016-07-29 | 2018-02-01 | Lan Bo Chen | Anti-ssea4 chimeric antigen receptors and their use for treating cancer |
CN110760001A (zh) * | 2019-07-29 | 2020-02-07 | 浙江启新生物技术有限公司 | Gm-csf敲低及其中和单链抗体分泌的嵌合抗原受体t细胞构建与应用 |
CN112210018A (zh) * | 2020-10-12 | 2021-01-12 | 广东昭泰体内生物医药科技有限公司 | 一种靶向gpc3的嵌合抗原受体及其应用 |
Non-Patent Citations (2)
Title |
---|
ROSALIE M. STERNER, SAKEMURA REONA, COX MICHELLE J., YANG NAN, KHADKA ROMAN H., FORSMAN CYNTHIA L., HANSEN MICHAEL J., JIN FANG, A: "GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 133, no. 7, 14 February 2019 (2019-02-14), US , pages 697 - 709, XP055613201, ISSN: 0006-4971, DOI: 10.1182/blood-2018-10-881722 * |
STERNER ROSALIE M., COX MICHELLE J., SAKEMURA REONA, KENDERIAN SAAD S.: "Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells", JOURNAL OF VISUALIZED EXPERIMENTS, JOVE, US, vol. 149, 22 July 2019 (2019-07-22), US , pages e59629 - e59629-6, XP009528961, ISSN: 1940-087X, DOI: 10.3791/59629 * |
Also Published As
Publication number | Publication date |
---|---|
AU2022263746A1 (en) | 2023-12-14 |
CN114934071A (zh) | 2022-08-23 |
GB2621770A (en) | 2024-02-21 |
GB202318060D0 (en) | 2024-01-10 |
JP2024515319A (ja) | 2024-04-08 |
CN114934071B (zh) | 2023-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11464806B2 (en) | Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells | |
JP6884155B2 (ja) | 癌治療のための併用免疫療法及びサイトカイン制御療法 | |
TW201934748A (zh) | Hpv專一性t細胞之產生技術 | |
CN108884440A (zh) | 用于增强免疫疗法的抗肿瘤活性的间充质干细胞 | |
US20240139248A1 (en) | Immunocompetent cell that expresses a cell surface molecule specifically recognizing human mesothelin, il-7 and ccl19 | |
JP7430202B2 (ja) | プラスミドの組合せおよび改変免疫細胞の調製におけるその適用 | |
WO2024119686A1 (zh) | 嵌合转换受体基因修饰的nk细胞制备方法及应用 | |
WO2022228538A1 (zh) | 一种表达免疫调节因子的car载体及其应用 | |
WO2022117049A1 (zh) | Nkg2d car-免疫细胞在抗衰老及老年相关疾病治疗中的应用 | |
US20200368281A1 (en) | Transforming growth factor beta-resistant natural killer cells | |
WO2021112055A1 (ja) | がんの処置に用いるny-eso-1含有人工アジュバントベクター細胞 | |
JP2005124568A (ja) | 細胞活性化方法及びこれを用いる細胞製造方法並びに医薬組成物 | |
KR20220092905A (ko) | 입양 면역요법 | |
CN110585427A (zh) | 提高机体免疫力的组合物及在抗成人t细胞白血病或鼻咽癌中的应用 | |
WO2023176938A1 (ja) | 腫瘍溶解性遺伝子改変麻疹ウイルスの新規用途 | |
CN108034669B (zh) | 一种抗vegf基因、及利用其修饰的t细胞、制备方法和应用 | |
Xu | EpCAM CAR T cells for the treatment of lung cancer brain metastasis-an in vivo imaging study in the mouse | |
Xia | Cancer Immunogene Therapy Using Viral Vectors Encoding Cytokines and Chimeric Antigen Receptors | |
Puigdelloses-Vallcorba | Immuno-virotherapy for glioblastoma: Characterization of Delta 24-ACT in combination with different immunomodulators as therapeutic approach | |
Liu | TGF-beta and cancer development: The role of TGF-beta in converting CD4+ CD25-T cells into CD4+ CD25+ T regulatory cells and a TbetaRIIDN-tk/ganciclovir suicide system in cancer gene therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22795008 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023566450 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 202318060 Country of ref document: GB Kind code of ref document: A Free format text: PCT FILING DATE = 20220429 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022263746 Country of ref document: AU Ref document number: AU2022263746 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022263746 Country of ref document: AU Date of ref document: 20220429 Kind code of ref document: A |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22795008 Country of ref document: EP Kind code of ref document: A1 |